January 25, 2018 / 12:14 PM / 3 months ago

BRIEF-Summit Therapeutics Says Muscle Damage Reduced After Treatment With Ezutromid

Jan 25 (Reuters) - Summit Therapeutics Plc:

* EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA FROM SUMMIT’S PHASEOUT DMD CLINICAL TRIAL

* SUMMIT THERAPEUTICS - TREATMENT WITH EZUTROMID RESULTED IN A STATISTICALLY SIGNIFICANT AND MEANINGFUL REDUCTION IN MUSCLE DAMAGE

* SUMMIT THERAPEUTICS - IN PHASEOUT DMD TRIAL, 14 OF 22 PATIENTS SHOWED DECREASE IN DEVELOPMENTAL MYOSIN, WITH 5 SHOWING OVER 40% REDUCTION

* SUMMIT THERAPEUTICS - TOP-LINE RESULTS OF PHASEOUT DMD TRIAL EXPECTED TO BE REPORTED IN Q3 2018

* SUMMIT THERAPEUTICS - TO CONDUCT RANDOMISED, PLACEBO CONTROLLED TRIAL TO SUPPORT ACCELERATED, CONDITIONAL APPROVAL OF EZUTROMID IN US, EU RESPECTIVELY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below